InMode Ltd. (NASDAQ:INMD) Shares Purchased by DDD Partners LLC

DDD Partners LLC grew its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 24.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,228,162 shares of the healthcare company’s stock after acquiring an additional 240,856 shares during the period. InMode accounts for approximately 3.7% of DDD Partners LLC’s investment portfolio, making the stock its 7th biggest holding. DDD Partners LLC owned approximately 1.48% of InMode worth $27,314,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Exchange Traded Concepts LLC bought a new position in shares of InMode during the 3rd quarter worth about $27,000. Brown Brothers Harriman & Co. bought a new position in shares of InMode during the 1st quarter worth about $41,000. Carmel Capital Partners LLC bought a new position in shares of InMode during the 3rd quarter worth about $36,000. Newbridge Financial Services Group Inc. bought a new position in shares of InMode during the 3rd quarter worth about $40,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of InMode by 97.1% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,472 shares of the healthcare company’s stock worth $45,000 after purchasing an additional 725 shares in the last quarter. 68.04% of the stock is currently owned by institutional investors and hedge funds.

InMode Stock Performance

NASDAQ:INMD opened at $21.20 on Thursday. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of 9.22 and a beta of 2.17. InMode Ltd. has a 52 week low of $18.57 and a 52 week high of $48.25. The firm has a 50-day moving average price of $22.58 and a two-hundred day moving average price of $23.57.

InMode (NASDAQ:INMD) last posted its quarterly earnings data on Tuesday, February 13th. The healthcare company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. InMode had a net margin of 40.22% and a return on equity of 29.80%. The firm had revenue of $126.80 million during the quarter, compared to analyst estimates of $124.77 million. During the same quarter last year, the business posted $0.69 EPS. The company’s revenue for the quarter was down 5.1% on a year-over-year basis. As a group, sell-side analysts forecast that InMode Ltd. will post 2.24 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. UBS Group raised their price target on shares of InMode from $24.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, February 14th. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $22.00 price target on shares of InMode in a research report on Thursday, December 7th. Finally, Barclays raised their price target on shares of InMode from $32.00 to $34.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $33.00.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.